Sensient Technologies
SXT NYSE Specialty Chemicals Financials FY2016βFY2025
Sensient Technologies' revenue rose 3.5% to $1.6 billion in fiscal 2025. Its operating margin was 12.8%, up from 12.3% a year earlier. Free cash flow was $38 million, down 60.8%. It paid out $70 million in dividends and buybacks, 181% of free cash flow. The diluted share count rose 0.5%.
What Sensient Technologies does
No business description yet.
- Legal name
- Sensient Technologies Corp
- Fiscal year ends
- December 31, 2025
- Latest annual report
- β
- Accession Β· CIK
- 0001140361-26-005311
0000310142
Revenue and margins
Sensient Technologies had $1.6B of revenue in fiscal 2025, up 3.5% on the year before.
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew 1.3% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $38.4M in fiscal 2025, 2.4% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Sensient Technologies returned $69.6M to shareholders in fiscal 2025, 181% of free cash flow. The diluted share count rose 0.5%.
Value Sensient Technologies yourself
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
Discounted cash flow
Value per share
β
Adds net cash of β$673M and divides by 42.6M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Earnings multiple
Value per share
β
Reference multiples: today 35.8x Β· peers 27.8x Β· sector 20.1x.
Balance sheet
Cash, debt and the ratios that show how comfortably Sensient Technologies can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $25.7M | $20.9M | $28.9M | $26.6M | $36.5M |
| Debt incl. finance leases | $512M | $631M | $645M | $614M | $709M |
| Net debt / EBITDA | 2.2x | 2.5x | 2.9x | 2.3x | 2.5x |
| Debt / equity | 0.6x | 0.6x | 0.6x | 0.6x | 0.6x |
| Interest coverage | 13.6x | 13.5x | 6.2x | 6.7x | 7.0x |
| Current ratio | 3.2x | 3.4x | 4.0x | 3.6x | 4.1x |
| Quick ratio | 1.4x | 1.4x | 1.4x | 1.3x | 1.5x |
| Total assets | $1.7B | $2.0B | $2.0B | $2.0B | $2.2B |
| Total liabilities | $807M | $982M | $961M | $963M | $1.1B |
| Shareholders' equity | $938M | $1,000M | $1.1B | $1.1B | $1.2B |
| Net debt (β = net cash) | $486M | $610M | $616M | $587M | $673M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.3M
2 insiders
Sold, 12 months
$234M
5 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | Mario FerruzziDirector | Sold | 1,200 | $129.48 | $0.2M | Form 4 |
| May 18, 2026 | Thierry HoangVP, Asia Pacific Group | Sold | 400 | $115.19 | $0.0M | Form 4 |
| May 4, 2026 | Thierry HoangVP, Asia Pacific Group | Sold | 439 | $114.15 | $0.1M | Form 4 |
| Apr 30, 2026 | Anstalt Winder10% owner | Sold | 2,127,566 | $109.69 | $233M | Form 4 |
| Apr 30, 2026 | Steven B MorrisPresident, Color Group | Sold | 200 | $114.58 | $0.0M | Form 4 |
| Dec 3, 2025 | Essie WhitelawDirector | Sold | 3,985 | $95.02 | $0.4M | Form 4 |
| Nov 20, 2025 | Essie WhitelawDirector | Sold | 533 | $93.22 | $0.0M | Form 4 |
| Nov 4, 2025 | David J. PlautzVP and Treasurer | Bought | 2,150 | $92.98 | $0.2M | Form 4 |
| Nov 3, 2025 | Joseph CarleoneDirector | Bought | 1,000 | $91.26 | $0.1M | Form 4 |
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 5 / 9 | 7 / 9 | 6 / 9 |
| Accruals ratio | β3.8% | β1.6% | 0.3% |
| Altman Z'' | 6.74 | 6.90 | 6.89 |
Similar companies
Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Sensient Technologies SXT | $5.7B | 3.5% | 12.9% | 2.4% | 8.9% | 35.8x | 6 | |
| Innospec IOSP | $2.4B | β3.7% | 7.3% | 5.0% | 11.1% | 20.1x | 6 | Compare β |
| Quaker Chemical KWR | $2.7B | 2.7% | 2.8% | 4.3% | 1.3% | 27.8x | 5 | Compare β |
| Minerals Technologies MTX | $2.0B | β2.2% | 2.3% | 4.2% | 1.6% | β | 4 | Compare β |
| Ingevity NGVT | $2.5B | β2.7% | 35.9% | 23.4% | 24.6% | 46.4x | 6 | Compare β |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.4B | $1.4B | $1.4B | $1.3B | $1.3B | $1.4B | $1.4B | $1.5B | $1.6B | $1.6B |
| Gross profit | $513M | $510M | β | β | $424M | $455M | $489M | $460M | $507M | $539M |
| Research and development | $40.9M | $40.9M | $43.0M | $40.1M | $38.5M | $34.3M | $42.2M | $48.1M | $49.1M | $52.9M |
| Operating income | $186M | $168M | $203M | $121M | $153M | $170M | $197M | $155M | $192M | $207M |
| Interest expense | $18.3M | $19.4M | $21.9M | $20.1M | $14.8M | $12.5M | $14.5M | $25.2M | $28.8M | $29.6M |
| Pretax income | $167M | $148M | $182M | $101M | $138M | $158M | $182M | $130M | $163M | $178M |
| Income tax | $44.4M | $58.8M | $24.2M | $19.0M | $28.4M | $38.7M | $41.3M | $36.5M | $38.1M | $43.1M |
| Net income | $126M | $89.6M | $157M | $82.0M | $110M | $119M | $141M | $93.4M | $125M | $135M |
| Diluted EPS | $2.82 | $2.03 | $3.70 | $1.94 | $2.59 | $2.81 | $3.34 | $2.21 | $2.94 | $3.16 |
| Diluted shares | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B |
| Cash flow | ||||||||||
| Cash from operations | $184M | $36.3M | $83.5M | $177M | $219M | $145M | $12.1M | $170M | $157M | $128M |
| Capital expenditure | $81.2M | $56.3M | $50.7M | $39.1M | $52.2M | $60.8M | $79.3M | $87.9M | $59.2M | $89.4M |
| Free cash flow | $102M | β$20.0M | $32.8M | $138M | $167M | $84.4M | β$67.3M | $81.8M | $97.9M | $38.4M |
| Depreciation and amortization | $47.0M | $48.5M | $53.2M | $55.0M | $49.6M | $52.1M | $52.5M | $57.8M | $60.3M | $61.1M |
| Stock-based compensation | $7.7M | $5.9M | $0.5M | β$0.7M | $5.6M | $9.6M | $16.1M | $8.9M | $10.1M | $13.9M |
| Acquisitions | $0.0M | $0.0M | $31.1M | $0.0M | $0.0M | $13.9M | $22.7M | $1.6M | $0.0M | $4.9M |
| Share buybacks | $50.1M | $87.2M | $76.7M | $0.0M | $0.0M | $42.5M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends paid | $49.6M | $54.0M | $57.4M | $62.2M | $66.1M | $66.7M | $68.9M | $69.2M | $69.4M | $69.6M |
| Dividends and buybacks | $99.7M | $141M | $134M | $62.2M | $66.1M | $109M | $68.9M | $69.2M | $69.4M | $69.6M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $25.9M | $29.3M | $31.9M | $21.2M | $24.8M | $25.7M | $20.9M | $28.9M | $26.6M | $36.5M |
| Total debt | $604M | $625M | $710M | $619M | $536M | $512M | $631M | $645M | $614M | $709M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $717M | $734M | $823M | $788M | $742M | $741M | $935M | $937M | $962M | $1.1B |
| Current liabilities | $214M | $216M | $215M | $201M | $216M | $232M | $272M | $236M | $271M | $264M |
| Inventory | $404M | $464M | $491M | $423M | $381M | $412M | $564M | $598M | $600M | $678M |
| Property and equipment, net | $477M | $499M | $491M | $437M | $446M | $447M | $483M | $505M | $492M | $539M |
| Total assets | $1.7B | $1.7B | $1.8B | $1.7B | $1.7B | $1.7B | $2.0B | $2.0B | $2.0B | $2.2B |
| Total liabilities | $832M | $872M | $965M | $859M | $807M | $807M | $982M | $961M | $963M | $1.1B |
| Shareholders' equity | $836M | $852M | $860M | $882M | $934M | $938M | $1,000M | $1.1B | $1.1B | $1.2B |
| Margins | ||||||||||
| Gross margin | 36.1% | 36.5% | β | β | 31.8% | 32.9% | 34.0% | 31.6% | 32.6% | 33.5% |
| Operating margin | 13.1% | 12.0% | 14.7% | 9.2% | 11.5% | 12.3% | 13.7% | 10.6% | 12.3% | 12.9% |
| EBITDA margin | 16.4% | 15.5% | 18.5% | 13.3% | 15.2% | 16.1% | 17.3% | 14.6% | 16.2% | 16.6% |
| Net margin | 8.9% | 6.4% | 11.4% | 6.2% | 8.2% | 8.6% | 9.8% | 6.4% | 8.0% | 8.3% |
| FCF margin | 7.2% | β1.4% | 2.4% | 10.4% | 12.5% | 6.1% | β4.7% | 5.6% | 6.3% | 2.4% |
| Returns | ||||||||||
| Return on capital | 9.5% | 7.1% | 11.8% | 6.5% | 8.3% | 8.9% | 10.0% | 6.8% | 8.8% | 8.9% |
| Return on capital employed | 12.6% | 11.3% | 13.0% | 7.7% | 10.0% | 11.2% | 12.2% | 8.9% | 10.9% | 11.1% |
| Return on equity | 15.0% | 10.6% | 18.4% | 9.4% | 12.1% | 12.7% | 14.5% | 9.1% | 11.8% | 11.9% |
| Return on assets | 7.5% | 5.3% | 8.9% | 4.6% | 6.3% | 6.8% | 7.6% | 4.7% | 6.2% | 6.3% |
| Growth | ||||||||||
| Revenue growth | 0.6% | β1.7% | β0.7% | β4.6% | 0.7% | 3.6% | 4.1% | 1.4% | 6.9% | 3.5% |
| Net income growth | 18.2% | β29.0% | 75.6% | β47.9% | 33.4% | 8.5% | 18.7% | β33.7% | 33.5% | 7.9% |
| EPS growth | 22.1% | β28.0% | 82.3% | β47.6% | 33.5% | 8.5% | 18.9% | β33.8% | 33.0% | 7.5% |
| FCF growth | 112.9% | β119.6% | β | 321.2% | 20.7% | β49.3% | β179.7% | β | 19.7% | β60.8% |
| Share count change | β3.0% | β1.8% | β3.5% | β0.5% | 0.1% | β0.2% | β0.1% | 0.1% | 0.4% | 0.5% |
| Financial health | ||||||||||
| Net debt / EBITDA | 2.5x | 2.8x | 2.6x | 3.4x | 2.5x | 2.2x | 2.5x | 2.9x | 2.3x | 2.5x |
| Debt / equity | 0.7x | 0.7x | 0.8x | 0.7x | 0.6x | 0.6x | 0.6x | 0.6x | 0.6x | 0.6x |
| Interest coverage | 10.1x | 8.7x | 9.3x | 6.0x | 10.3x | 13.6x | 13.5x | 6.2x | 6.7x | 7.0x |
| Current ratio | 3.4x | 3.4x | 3.8x | 3.9x | 3.4x | 3.2x | 3.4x | 4.0x | 3.6x | 4.1x |
| Quick ratio | 1.5x | 1.3x | 1.6x | 1.8x | 1.7x | 1.4x | 1.4x | 1.4x | 1.3x | 1.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 5.7% | 4.0% | 3.7% | 3.0% | 3.9% | 4.4% | 5.5% | 6.0% | 3.8% | 5.6% |
| Stock comp / revenue | 0.5% | 0.4% | 0.0% | β0.1% | 0.4% | 0.7% | 1.1% | 0.6% | 0.7% | 0.9% |
| Payouts / FCF | 97.4% | β | 409.2% | 45.0% | 39.7% | 129.3% | β | 84.6% | 70.9% | 181.2% |
| Quality scores | ||||||||||
| Piotroski F-score | 8.0 | 6.0 | 5.0 | 6.0 | 6.0 | 8.0 | 7.0 | 5.0 | 7.0 | 6.0 |
| Altman Z'' | 6.5 | 6.3 | 6.6 | 6.6 | 6.7 | 6.8 | 6.7 | 6.7 | 6.9 | 6.9 |
| Accruals ratio | β3.4% | 3.1% | 4.2% | β5.3% | β6.3% | β1.5% | 6.9% | β3.8% | β1.6% | 0.3% |
Source: SEC EDGAR XBRL filings (CIK 0000310142). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.